ASS für alle?

Zusammenfassung

Acetylsalicylsäure in einer Dosierung von 75-160 mg/Tag ist nachweisbar wirksam zur Primärprävention von Herzinfarkten und zur Sekundärprävention von Schlaganfällen. Unter der Beachtung von Gefahren durch Nebenwirkungen ist eine Behandlung nahezu immer sinnvoll in der Sekundärprävention nach Herzinfarkt, ischämischen Hirninsult und bei KHK. In der Primärprävention kann eine Behandlung ab 1-1,5 %/Jahr Gesamtrisiko für Gefäßereignisse empfohlen werden.

Abstract

Aspirin 75-160 mg/d is effective in primary prevention of myocardial infarction and secondary prevention of ischaemic stroke. Considering potential hazards of side-effects, treatment is almost always justified in secondary prevention after MI, stroke, or in CVD. In primary prevention, treatment can be recommended if overall CVD-risk exceeds 1-1.5 % per year.

Schlüsselwörter

ASS - Kardivaskuläre Prävention - Schlaganfall - Herzinfarkt

Key words

Aspirin - cardiovascular prevention - stroke - myocardial infarction

Literatur

• 1 Anderson K M, Wilson P WF, Odell P M, Kannel W B. An updated coronary risk factor profile: a statement for health professionals.  Circulation. 1991;  83 356-362
• 2 Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
• 3 Arzneimittelbrief . Absetzen von Azetylsalizylsäure vor Operationen.  Der Arzneimittelbrief. 2000;  34 56
• 4 Arzneimittelbrief . Nochmals: Absetzen von Azetylsalizylsäure vor Operationen.  Der Arzneimittelbrief. 2000;  34 71-72
• 5 Boissel J P. Individualizing aspirin therapy for prevention of cardiovascular events.  JAMA. 1998;  280 1949-1950
• 6 Borgers D. Universelle primärmedizinische Medikation des kardiovaskulären Risikos: ein WHO-Vorschlag.  Z Allg Med. 2003;  79 244-247
• 7 Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an update to 2001.  Eur J Cancer Prev. 2002;  11 535-542
• 8 Broe G A, Grayson D A, Creasey H M, Waite L M, Casey B J, Bennett H P. et al . Anti-inflammatory drugs protect against Alzheimer disease at low doses.  Arch Neurol. 2000;  57 1586-1591
• 9 CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  Lancet. 1996;  348 1329-1339
• 10 Corley D A, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis.  Gastroenterology. 2003;  124 47-56
• 11 D'Agostino R B, Russell M W, Huse D M, Ellison C, Silbershatz H, Wilson P W. et al . Primary and subsequent coronary risk appraisal: new results from the Framingham study.  Am Heart J. 2000;  139 272-281
• 12 De Gaetano G.. Collaborative Group of the Primary Prevention Project . Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project.  Lancet. 2001;  357 89-95
• 13 De Schryver E L, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease (Cochrane Review). In: The Cochrane Library, Issue 1. Update Software, Oxford 2003
• 14 Diener H C, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A.. European Stroke Prevention Study . 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.  J Neurol Sci. 1996;  143 1-13
• 15 Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.  BMJ. 1998;  316 1303-1309
• 16 Elwood P C, Cochrane A L, Burr M L, Sweetnam P M, Williams G, Welsby E, Hughes S J, Renton R. A randomised controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction.  Br Med J. 1974;  1 436-440
• 17 ETDRS Investigators . Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14.  JAMA. 1992;  268 1292-1300
• 18 Rote Liste .Fachinformation Azetylsalizylsäure (A5). Edition Cantor Verlag 2003, Aulendorf
• 19 Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.  J Neurol Neurosurg Psychiatry. 1991;  54 1044-1054
• 20 Flower R. What are all the things that aspirin does?.  BMJ. 2003;  327 572-573
• 21 Hankey G J, Warlow C P. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations.  Lancet. 1999;  354 1457-1463
• 22 Hansson L, Zanchetti A, Carruthers S G, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn K H, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.  HOT Study Group.  Lancet. 1998;  351 1755-1762
• 23 Hass W K, Easton J D, Adams H P, Pryse-Phillips W, Molony B A, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine.  Aspirin Stroke Study Group  N Engl J Med. 1989;  321 501-507
• 24 Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.  Ann Intern Med. 2002;  136 161-172
• 25 Heart Outcomes Prevention Evaluation Study Investigators . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.  Lancet. 2000;  355 253-259
• 26 Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial.  Lancet. 2002;  360 7-22
• 27 Hedman J, Kaprio J, Poussa T, Nieminen M M. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study.  Int J Epidemiol. 1999;  28 717-722
• 28 Hoigne R V, Braunschweig S, Zehnder D, Kuenzi U P, Hess T, Leuenberger P. Drug-induced attack of bronchial asthma in inpatients: a 20-year-survey of the Comprehensive Hospital Drug Monitoring Programme on adverse drug reactions, Berne/St. Gallen.  Eur J Clin Pharmacol. 1997;  53 81-82
• 29 Homepage der Firma Bayer (besucht am 30.10.2003) .http://www.aspirin.com/world_of_aspirin_de.html
• 30 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group . Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2.  Lancet. 1988;  2 349-360
• 31 Kjeldsen S E, Kolloch R E, Leonetti G, Mallion J M, Zanchetti A, Elmfeldt D, Warnold I, Hansson L. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment.  J Hypertens. 2000;  18 629-642
• 32 Lewis H D, Davis J W, Archibald D G, Steinke W E, Smitherman T C, Doherty J E, Schnaper H W, LeWinter M M, Linares E, Pouget J M, Sabharwal S C, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.  N Engl J Med. 1983;  309 396-403
• 33 Marshall T. Coronary heart disease prevention: insights from modelling incremental cost effectiveness.  BMJ. 2003;  327 1264
• 34 Medical research council's General Practice Research Framework . Thrombosis prevention trial: randomized trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart diseases in men at increased risk.  Lancet. 1998;  351 233-241
• 35 Niessen L W, Dippel D W, Limburg M. Calculation of costs of stroke, cost effectiveness of stroke units and secondary prevention in patients after a stroke, as recommended by revised CBO practice guideline ‘Stroke’.  Ned Tijdschr Geneeskd. 2000;  144 1959-1964
• 36 Paterson J R, Lawrence J R. Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer.  QJM. 2001;  94 445-448
• 37 Pearson T A, Blair S N, Daniels S R, Eckel R H, Fair J M, Fortmann S P, Franklin B A, Goldstein L B, Greenland P, Grundy S M, Hong Y, Miller N H, Lauer R M, Ockene I S, Sacco R L, Sallis J F, Smith S C, Stone N J, Taubert K A. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee.  Circulation. 2002;  106 388-391
• 38 Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S. et al . Randomised trial of prophylactic daily aspirin in British male doctors.  BMJ. 1988;  296 313-316
• 39 Pocock S J, McCormack V, Gueyffier F, Boutitie F, Fagard R H, Boissel J P. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials.  BMJ. 2001;  323 75-81
• 40 Redman A R, Ryan G J. Analysis of trials evaluating combinations of acetylsalicylic acid and dipyridamole in the secondary prevention of stroke.  Clin Ther. 2001;  23 1391-1408
• 41 Rexrode K M, Lee I M, Cook N R, Hennekens C H, Buring J E. Baseline characteristics of participants in the Women's Health Study.  J Womens Health Gend Based Med. 2000;  9 19-27
• 42 Sanmuganathan P S, Ghahramani P, Jackson P R, Wallis E J, Ramsay L E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.  Heart. 2001;  85 265-271
• 43 Settipane R A, Constantine H P, Settipane G A. Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review.  Allergy. 1980;  35 149-154
• 44 Steering Committee of the Physicians' Health Study Research Group . Final report on the aspirin component of the ongoing Physicians' Health Study.  N Engl J Med. 1989;  321 129-135
• 45 Stewart W F, Kawas C, Corrada M, Metter E J. Risk of Alzheimer's disease and duration of NSAID use.  Neurology. 1997;  48 626-632
• 46 The SALT Collaborative Group . Swedish Aspirin Low-Dose-trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events.  Lancet. 1991;  338 1345-1349
• 47 Thun M J, Henley S J, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.  J Natl Cancer Inst. 2002;  94 252-266
• 48 Wald N J, Law M R. A strategy to reduce cardiovascular disease by more than 80 %.  BMJ. 2003;  326 1419-1425
• 49 Weisman S M, Graham D Y. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.  Arch Intern Med. 2002;  162 2197-2202